review. ne was 35.04 ± 22.24gm. The mean PSA level was 12.69 ± The m, and two cases of prostate adenocarcinoma were found. The mean operative time was 111.83 ± and t minutes, and 25.11 ± minutesgm of specimen was collected. The mean days of hospital stay was 5.69 ± m3.02 days, and 5.29 ± days, and 5.29 as collected. The mean days of hospital stay was 5.69 ive time was 111.83 ted with a o post-op blood transfusion was given. No post-op urine retention was noted. The resected weight of prostate

more »

... larger than previous 2 groups, however, length of hospital stay is not significant among the 3 groups. Conclusion: The new laser modality, MultiPulse ® Tm+1470 laser, is available for TUR-P, and the result is comparable with previous laser prostatectomy. Further study with larger patients group and long-term follow-up is mandutory. Purpose: The aim of this study is to investigate the risk of diabetes mellitus (DM) after 5-alpha-reductase inhibitor (5ARI) therapy for benign prostate hyperplasia (BPH) using the National Health Insurance Research Database (NHIRD) in Taiwan. Materials and Methods: In total, 1298 adult patients newly diagnosed with BPH and who used more than 28 cumulative defined daily doses (cDDD) of 5ARI were recruited as the therapy group cohort, along with 12887 subjects who did not use more than 28 cDDD of 5ARI as a control group from 2002 to 2009. Each patient was monitored for five years (from 2003 to 2008) to identify those who subsequently developed DM. A Cox proportional hazards model was used to compare the risk of DM between the study and comparison cohorts after adjusting for possible confounding risk factors. Results: Patients who received 5ARI therapy had a lower cumulative rate of DM than those who did not receive 5ARI during the five-year follow-up period (3.5% vs. 5.3%, p ¼ 0.003). In sub-group analysis, among the BPH patients aged <65 years, the five-year DM events hazard ratio (HR) of 5ARI users was lower than that of non-users (HR: 0.47, 95% confidence interval (CI): 0.24e0.91; p ¼ 0.026). Conclusion: Therapy with 5ARI may decrease the five-year risk of DM in the BPH patients younger than 65 years. Further mechanistic research is warranted to validate the results.